uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
New perspectives in managing myeloproliferative disorders: focus on the patient
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Hematologi)
2009 (English)In: Hematological Oncology, ISSN 0278-0232, E-ISSN 1099-1069, Vol. 27, no Suppl.1, 5-7 p.Article in journal (Refereed) Published
Abstract [en]

Risk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500 x 10(9), cardiovascular risk factors should be addressed. In addition, premorbidity with regard to possible side effects of platelet-reducing drugs as well as the impact on quality of life of such side effects should be considered. The near-to-normal life expectancy and long term nature of treatment also makes it necessary to consider the potential leukaemogenic effects of some cytostatic drugs.

Place, publisher, year, edition, pages
2009. Vol. 27, no Suppl.1, 5-7 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-108752DOI: 10.1002/hon.910ISI: 000267240100003PubMedID: 19468983OAI: oai:DiVA.org:uu-108752DiVA: diva2:240631
Available from: 2009-09-29 Created: 2009-09-29 Last updated: 2011-04-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Medical Sciences
In the same journal
Hematological Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 177 hits
ReferencesLink to record
Permanent link

Direct link